Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EPZMNASDAQ:ODTNASDAQ:SPPINASDAQ:YMAB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AYMABY-mAbs Therapeutics$12.94-4.9%$15.69$4.60▼$20.90$567.68M0.78402,281 shs354,457 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPZMEpizyme0.00%0.00%0.00%0.00%0.00%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%-14.17%YMABY-mAbs Therapeutics-20.92%-17.47%-5.81%+4.93%+47.45%Things Are Not Normal in America – Here’s What to Do (Ad)Get Out of the Dollar Before May 15 A Wall Street legend and our friend has just warned 896,000 Americans to prepare for May 15.This could be your solution.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPZMEpizymeN/AN/AN/AN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AYMABY-mAbs Therapeutics1.9837 of 5 stars3.21.00.00.01.74.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPZMEpizymeN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/ASPPISpectrum Pharmaceuticals2.00HoldN/AN/AYMABY-mAbs Therapeutics2.33Hold$16.5728.06% UpsideCurrent Analyst RatingsLatest ODT, YMAB, EPZM, and SPPI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.003/4/2024YMABY-mAbs TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.003/4/2024YMABY-mAbs TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $26.002/20/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $21.002/12/2024YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $18.00(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72ODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/ASPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87YMABY-mAbs Therapeutics$84.82M6.69N/AN/A$2.32 per share5.58Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AODTOdonate Therapeutics-$126.35MN/A0.00N/AN/AN/AN/AN/AN/ASPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AYMABY-mAbs Therapeutics-$21.43M-$0.49N/AN/AN/A-25.26%-20.72%-16.28%8/8/2024 (Estimated)Latest ODT, YMAB, EPZM, and SPPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023YMABY-mAbs Therapeutics-$0.19-$0.02+$0.17-$0.02$21.72 million$23.36 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPZMEpizymeN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPZMEpizymeN/A5.355.19ODTOdonate TherapeuticsN/AN/AN/ASPPISpectrum PharmaceuticalsN/A2.712.38YMABY-mAbs TherapeuticsN/A5.525.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPZMEpizyme76.45%ODTOdonate TherapeuticsN/ASPPISpectrum Pharmaceuticals21.67%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipEPZMEpizyme23.40%ODTOdonate Therapeutics48.90%SPPISpectrum Pharmaceuticals2.70%YMABY-mAbs Therapeutics21.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEPZMEpizyme250168.33 million128.97 millionOptionableODTOdonate Therapeutics14528.53 million14.58 millionNot OptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableYMABY-mAbs Therapeutics10043.87 million34.44 millionOptionableODT, YMAB, EPZM, and SPPI HeadlinesSourceHeadlineY-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...finance.yahoo.com - May 9 at 6:35 AMQ1 2024 Y-mAbs Therapeutics Inc Earnings Callfinance.yahoo.com - May 9 at 1:35 AMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $17.21marketbeat.com - May 8 at 3:54 PMBuy Rating Affirmed for Y-Mabs Therapeutics Amid Strong Danyelza Sales and Promising SADA Radiotherapy Platformmarkets.businessinsider.com - May 8 at 3:34 PMYMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024investorplace.com - May 7 at 11:03 PMY-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developmentstmcnet.com - May 7 at 7:33 PMY-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimatesfinance.yahoo.com - May 7 at 7:33 PMY-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimateszacks.com - May 7 at 6:56 PM43,700 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by Sapient Capital LLCmarketbeat.com - May 7 at 8:57 AMY-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Tuesdayamericanbankingnews.com - May 5 at 5:52 AMY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Brokeragesamericanbankingnews.com - May 5 at 1:44 AMY-mAbs Therapeutics (YMAB) Set to Announce Quarterly Earnings on Tuesdaymarketbeat.com - April 30 at 1:06 PMY-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024globenewswire.com - April 26 at 7:05 AMY-mAbs to Present at 2024 ASCO Annual Meetingglobenewswire.com - April 25 at 4:05 PMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7%marketbeat.com - April 23 at 4:47 PMNew Strong Buy Stocks for April 19thzacks.com - April 19 at 7:50 AMY-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%finance.yahoo.com - April 18 at 1:21 PMNew Strong Buy Stocks for April 17thzacks.com - April 17 at 8:30 AMY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4%marketbeat.com - April 11 at 11:58 AMY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Analystsmarketbeat.com - April 10 at 2:30 AMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 3.3% marketbeat.com - April 9 at 11:46 AMWall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Betzacks.com - March 28 at 10:56 AMYmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?zacks.com - March 20 at 8:40 AMY-mAbs Therapeutics Finance Chief Bo Kruse Resignsmarketwatch.com - March 15 at 8:31 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEpizymeNASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Odonate TherapeuticsNASDAQ:ODTOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Spectrum PharmaceuticalsNASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Y-mAbs TherapeuticsNASDAQ:YMABY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.